Antifungal management in ICU careful follow-up of voriconazole prescription needed!

Abstract

Over the last 5 years, viral induced acute respiratory distress syndrome (ARDS) has emerged as a major risk factor for invasive fungal infections in ICU patients worldwide [1, 2]. Pulmonary aspergillosis, being reported in 15–27% of critical COVID-19 patients [2, 3] and in nearly 20% of Influenza associated ARDS patients [1], appears to be the main fungal infection involved.